Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds Sells 2,053 Shares

Masimo Co. (NASDAQ:MASI - Get Free Report) Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Masimo Price Performance

Shares of Masimo stock traded down $4.62 during trading hours on Tuesday, reaching $168.16. The company's stock had a trading volume of 370,408 shares, compared to its average volume of 620,695. The firm has a 50 day moving average price of $174.86 and a 200-day moving average price of $158.33. Masimo Co. has a one year low of $101.61 and a one year high of $194.88. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The stock has a market cap of $9.07 billion, a P/E ratio of 115.97 and a beta of 1.04.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. On average, analysts predict that Masimo Co. will post 4.1 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On Masimo

Several hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in shares of Masimo by 31.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 60 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 64 shares during the period. Blue Trust Inc. lifted its position in shares of Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after purchasing an additional 71 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Masimo by 0.8% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider's stock worth $1,622,000 after purchasing an additional 82 shares during the period. Finally, Thrivent Financial for Lutherans lifted its position in shares of Masimo by 0.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider's stock worth $1,728,000 after purchasing an additional 83 shares during the period. 85.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on MASI shares. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a report on Wednesday, February 26th. Wells Fargo & Company lifted their price target on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Raymond James lifted their price target on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a report on Friday, December 27th. Piper Sandler lifted their price target on shares of Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Stifel Nicolaus restated a "buy" rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $194.80.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.